$EPZM Epizyme, Inc. Insider Trading Week 12/2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Epizyme, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Epizyme, Inc. in week 12/2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Sell | S | 15.28 | 212 | 3,239 | 4,961 | 5.2 K to 5 K (-4.10 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Grant | A | 0.00 | 1,556 | 0 | 5,173 | 3.6 K to 5.2 K (+43.02 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Sell | S | 15.28 | 1,243 | 18,993 | 15,437 | 16.7 K to 15.4 K (-7.45 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Grant | A | 0.00 | 1,690 | 0 | 16,680 | 15 K to 16.7 K (+11.27 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 15.28 | 1,243 | 18,993 | 51,798 | 53 K to 51.8 K (-2.34 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 1,563 | 0 | 53,041 | 51.5 K to 53 K (+3.04 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 16.14 | 73,409 | 1,184,821 | 73,409 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 9.12 | 48,727 | 444,390 | 298,737 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Sell | S | 15.28 | 212 | 3,239 | 4,961 | 5.2 K to 5 K (-4.10 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 12.45 | 2,371 | 29,519 | 333,333 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Beaulieu Joseph | Corporate Controlle ... | Grant | A | 0.00 | 1,556 | 0 | 5,173 | 3.6 K to 5.2 K (+43.02 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 8.98 | 79,167 | 710,920 | 333,333 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 15.28 | 3,285 | 50,195 | 254,371 | 257.7 K to 254.4 K (-1.27 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Sell | S | 15.28 | 1,243 | 18,993 | 15,437 | 16.7 K to 15.4 K (-7.45 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 7,000 | 0 | 257,656 | 250.7 K to 257.7 K (+2.79 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | TOMBESI PAOLO | Chief Financial Off ... | Grant | A | 0.00 | 1,690 | 0 | 16,680 | 15 K to 16.7 K (+11.27 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 113,393 | 0 | 250,656 | 137.3 K to 250.7 K (+82.61 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | J | 0.00 | 56,537 | 0 | 80,726 | 137.3 K to 80.7 K (-41.19 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Sell | S | 15.28 | 1,243 | 18,993 | 51,798 | 53 K to 51.8 K (-2.34 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Sell | S | 15.28 | 1,243 | 18,993 | 71,991 | 73.2 K to 72 K (-1.70 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Ros Matthew | See Remarks | Grant | A | 0.00 | 1,563 | 0 | 53,041 | 51.5 K to 53 K (+3.04 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 1,575 | 0 | 73,234 | 71.7 K to 73.2 K (+2.20 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | A | 16.14 | 73,409 | 1,184,821 | 73,409 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 9.12 | 48,727 | 444,390 | 298,737 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 12.45 | 2,371 | 29,519 | 333,333 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Option Exercise | J | 8.98 | 79,167 | 710,920 | 333,333 | |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | S | 15.28 | 3,285 | 50,195 | 254,371 | 257.7 K to 254.4 K (-1.27 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 7,000 | 0 | 257,656 | 250.7 K to 257.7 K (+2.79 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Grant | A | 0.00 | 113,393 | 0 | 250,656 | 137.3 K to 250.7 K (+82.61 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Bazemore Robert B | President & CEO | Sell | J | 0.00 | 56,537 | 0 | 80,726 | 137.3 K to 80.7 K (-41.19 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Sell | S | 15.28 | 1,243 | 18,993 | 71,991 | 73.2 K to 72 K (-1.70 %) |
| Mar 26 2020 | EPZM | Epizyme, Inc. | Agarwal Shefali | Chief Medical Offic ... | Grant | A | 0.00 | 1,575 | 0 | 73,234 | 71.7 K to 73.2 K (+2.20 %) |